T1D Pregnancy & Me

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorJaeb Center for Health Research

About this trial

T1D Pregnancy \& Me will partner with pregnant participants living with type 1 diabetes (T1D) in the United States to collect real-world data on management of T1D in pregnancy. This is a remote study where participants can complete online surveys and share device data (continuous glucose monitor (CGM) data and insulin data). Through the collection of CGM, insulin, and pregnancy outcome data, the study will provide important information to understand how diabetes is being managed during pregnancy. These data will provide much needed evidence to guide modern management of diabetes during pregnancy with a goal of improving care and outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥18 years

Clinical diagnosis of presumed T1D for at least 6 months duration

Less than 15 weeks gestation at time of enrollment based on due date from provider

Planned CGM use on a regular basis (e.g., ≥10 out of 14 days) and willing to continue using CGM regularly with no plans to discontinue CGM use during the study

Disqualifiers

Multiple pregnancy

Current renal dialysis or plan to begin renal dialysis during the study

History of liver cirrhosis

Active cancer treatment with systemic chemotherapy

Trial population

Pregnant adults with type 1 diabetes from across the United States who use a continuous glucose monitor.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Hybrid closed loop insulin delivery system

    Device

    Hybrid closed loop insulin delivery system is a system that uses a continuous glucose monitor (CGM) to send blood glucose values to an insulin pump that automatically provides insulin based on the blood glucose value and anticipated future level.

Treatment groups

500 Participants
are divided into 2 treatment groups
Group A: HCL Use1 intervention
Group B: HCL Non-Use0 interventions

Trial outcomes

Primary outcomes

1

CGM Outcome (BG 63-140 mg/dl)

Percentage of time spent with glucose 63-140 mg/dl

Time frame
Up to 37 weeks gestation

Secondary outcomes

1

CGM Outcome (BG<63 mg/dl)

Percentage time spent with glucose \<63 mg/dl

Time frame
Up to 37 weeks gestation
2

CGM Outcome (BG<54 mg/dl)

Percentage time spent with glucose \<54 mg/dl

Time frame
Up to 37 weeks gestation
3

CGM Outcome (BG>140 mg/dl)

Percentage time spent with glucose \>140 mg/dl

Time frame
Up to 37 weeks gestation

Other outcomes

1

Hypertensive disorder of pregnancy

Gestational hypertension or preeclampsia

Time frame
Up to 37 weeks gestation
2

LGA Status (defined as birthweight percentile > 90th)

Large gestational age birthweight

Time frame
At birth
3

Preterm delivery

Preterm delivery

Time frame
Delivery after 20 weeks and before 37 weeks gestation
4

Neonatal Morbidity

Hypoglycemia, hyperbilirubinemia, respiratory distress, or birth trauma

Time frame
At birth

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jaeb Center for Health Research

Lead sponsor

The Leona M. and Harry B. Helmsley Charitable Trust

Collaborator